AMG 193, a clinical stage MTA-cooperative PRMT5 inhibitor, drives antitumor activity preclinically and in patients with MTAP-deleted cancers. Cancer Discov. Published September 16, 2024. doi:10.1158/2159-8290.CD-24-0887 4. AMG 193 alone or in combination with other therapies in subjects with ...
AMG 193 potently inhibits MTAP-null cancer cell lines and patient-derived xenografts. Methods: NCT05094336 is a first-in-human (FIH), multicenter, open-label, phase 1/1b/2 trial evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and efficacy of AMG 193 in patients ...
同时该公司也宣布,FDA暂停了AMG 513的I期临床研究,为保护试验参与者免受不合理风险。安进未说明临床暂停的原因,只表示与药物本身无关,且“正在讨论重启研究的途径”。AMG 513当前未公布靶点或作用机制,据clinicaltrials.gov网站显示,安进在2024年9月注册了AMG 513治疗减重的I期临床试验。试验预计在2026年3月完成,...
[1]. Block GA, et al. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. JAMA. 2017 Jan 10;317(2):156-164. 其他产品列表: ...
Phase 1 clinical trial of AMG 340, a prostate-specific membrane antigen (PSMA)-targeted T-cell engager with a novel low-affinity CD3 binding domain designed to mitigate toxicity for the treatment of metastatic castration-resistant prostate cancer (mCRPC)....
Trial InformationBone & Cancer Foundation
Further in depth studies examining the biological effects of trebananib on marrow angiogenesis and clinical response in AML patients are ongoing.Disclosures: Becker: Millenium: Research Funding. [1]: http://ClinicalTrials.gov [2]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01555268&...